Ingenuity Systems Extends Enterprise-Level Software Agreement with GlaxoSmithKline
Complete the form below to unlock access to ALL audio articles.
Ingenuity Systems has announced that they have extended and expanded their existing license agreement with GlaxoSmithKline for access to Ingenuity Pathways Analysis (IPA) software.
The new agreement enables GSK to provide enterprise-wide IPA access to researchers for assessment of the signaling and metabolic pathways, molecular networks, and biological processes that are most significant to disease targets. In addition, GSK will also use Ingenuity's content and proprietary algorithms.
"We are very pleased that GSK will now be able to leverage IPA and other Ingenuity information solutions at the enterprise level," stated Jake Leschly, CEO, Ingenuity Systems.
"Many discovery programs at GSK have already successfully used IPA to understand the complex relationship between pathways and disease. Research teams across the organization will now be able to use these insights to make effective decisions as to which drug targets and compounds to pursue."
